Latest News and Press Releases

Glycotope to present platform approach for development of anti-GlycoTarget antibodies at 2024 AACR Meeting Berlin, Germany, 08 April, 2024 – Glycotope GmbH, a biotechnology company utilizing a...

Glycotope and Evotec enter licensing agreement to combine Glycotope antibodies and Evotec’s immune cell engager platform Berlin, Germany, 11 December 2023 – Glycotope GmbH (Glycotope) has signed...

Glycotope Presents anti-GlycoTarget Antibodies at the 2023 Society for Immunotherapy of Cancer (SITC) Meeting Berlin, Germany, 03 November, 2023 – Glycotope GmbH, a biotechnology company with a...

Seoul, South Korea, and Berlin, Germany October 16, 2023 – LegoChem Biosciences Inc. (LCB) and Glycotope GmbH (Glycotope) have entered into an exclusive worldwide licensing agreement to develop an...

Glycotope and Max Delbrück Center enter into research collaboration to explore combination of GlycoTargets and CAR technology Berlin, Germany, 25 September 2023 – Glycotope GmbH (Glycotope) and...

Glycotope Presents Glyco-Engineered Cell Lines at the 2023 American Association for Cancer Research (AACR) MeetingBerlin, Germany, 17 April, 2023 – Glycotope GmbH, a biotechnology company...

Therabest and Glycotope to assess Therabest’s iPSC-derived NK cell product TB-100 in combination with Glycotope’s GT-00AxIL15 immuno-cytokine for development in triple negative breast cancer San...

Glycotope Presents GlycoTarget Platform and New Data on Platform-Derived anti-LYPD3 Antibody at 2022 Society for Immunotherapy of Cancer (SITC) Meeting Berlin, Germany, 08 November, 2022 –...

LegoChem Biosciences and Glycotope Announce Research Collaboration and License Agreement for an Antibody for use as Antibody Drug Conjugate July 12, 2022 Seoul, South Korea, and Berlin, Germany -...

Glycotope Presents New Data on Antibodies and Fusion-Proteins against GlycoTargets at the 2022 American Association for Cancer Research (AACR) Meeting Berlin, Germany, 08 April, 2022 – Glycotope...